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Opioids are powerful analgesics but the clinical utility of these compounds is reduced by
aversive outcomes, including the development of affective and substance use disorders.
Opioid systems do not function in isolation so understanding how these interact with
other neuropharmacological systems could lead to novel therapeutics that minimize
withdrawal, tolerance, and emotional dysregulation. The cannabinoid system is an
obvious candidate as anatomical, pharmacological, and behavioral studies point to
opioid-cannabinoid interactions in themediation of these processes. The aim of our study
is to uncover the role of specific cannabinoid and opioid receptors in addiction-related
behaviors, specifically nociception, withdrawal, anxiety, and depression. To do so, we
tested the effects of a selective CB1 agonist, arachidonyl-2-chloroethylamide (ACEA),
on mouse behavior in tail immersion, naloxone-precipitated withdrawal, light-dark, and
splash tests. We examined cannabinoid-opioid interactions in these tests by comparing
responses of wildtype (WT) mice to mutant lines lacking either Mu or Delta opioid
receptors. ACEA, both acute or repeated injections, had no effect on nociceptive
thresholds in WT or Mu knockout (KO) mice suggesting that analgesic properties of
CB1 agonists may be restricted to chronic pain conditions. The opioid antagonist,
naloxone, induced similar levels of withdrawal in all three genotypes following ACEA
treatment, confirming an opioidergic contribution to cannabinoid withdrawal. Anxiety-like
responses in the light-dark test were similar across WT and KO lines; neither acute nor
repeated ACEA injections modified this behavior. Similarly, administration of the Delta
opioid receptor antagonist, naltrindole, alone or in combination with ACEA, did not alter
responses of WT mice in the light-dark test. Thus, there may be a dissociation in the
effect of pharmacological blockade vs. genetic deletion of Delta opioid receptors on
anxiety-like behavior in mice. Finally, our study revealed a biphasic effect of ACEA on
depressive-like behavior in the splash test, with a prodepressive state induced by acute
exposure, followed by a shift to an anti-depressive state with repeated injections. The
initial pro-depressive effect of ACEA was absent in Mu KO mice. In sum, our findings
confirm interactions between opioid and cannabinoid systems in withdrawal and reveal
reduced depressive-like symptoms with repeated CB1 receptor activation.
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INTRODUCTION
Opioid and cannabinoid systems both play a critical role in
a number of addiction-related behaviors, such as analgesia,
reward, and emotional processing (1, 2). This commonality of
function may reflect colocalization of opioid and cannabinoid
receptors in brain regions implicated in each process and/or
a common mechanism of receptor activation. In terms of the
latter, Mu (MOP), Delta (DOP), and Kappa (KOP) opioid
receptors, as well as both cannabinoid receptors (CB1 and CB2),
are all coupled to inhibitory G proteins. Similarly, anatomical
distribution of the three opioid receptors (3, 4) overlaps with
CB1 receptor distribution (1) in many areas of the central
nervous system (CNS). In contrast, anatomical localization of
CB2 receptors in the CNS is not well studied. Indeed, initial
reports described CB2 expression in immune cells (5, 6),
although more recent work confirmed central expression of
these receptors (7–9). Consequently, the anatomical relationship
between CB2 receptors and either CB1 or opioid receptors
is not known. Importantly, colocalization of opioid and CB1
receptors has been reported in the spinal cord, a critical
site for antinociception (10–12), and in higher brain regions
associated with emotional processing (13). This pattern of co-
expression suggests that cannabinoid-opioid interactions may
mediate behavioral responses related to pain relief and addiction
(1, 6, 14), a process that may involve the formation of receptor
heteromers (15).
Pharmacological and genetic knockout studies confirm
interactive effects of opioid and CB1 receptors in antinociception
(16) and behaviors related to addiction (17). For example,
pharmacological blockade of either opioid or cannabinoid
receptors with selective antagonists attenuates behavioral
responses induced by an agonist of the other system (14). In
addition, genetic inactivation of MOP receptors, producing
knockout (KO) mice, decreases physical dependence induced
by chronic administration of cannabinoid agonists (18, 19)
and reduces the reinforcing properties of these drugs (18).
Conversely, inactivation of CB1 receptors inhibits the rewarding
properties of a MOP receptor agonist (19–21).
Most studies examining opioid mechanisms in pain relief
focus on MOP receptors because of the potent analgesic
properties of MOP agonists, such as morphine. Unfortunately,
the therapeutic utility of these compounds is often limited as
repeated use can lead to both tolerance and addiction (22). One
suggestion for increasing clinical efficacy is to combine MOP and
cannabinoid agonists, as this leads to increased analgesia (23–25)
with fewer side effects (26). Development of these combination
drugs depends on a better understanding of opioid-cannabinoid
interaction in antinociception and addiction-related behaviors
(e.g., tolerance, withdrawal, and emotional processing). To
date, the majority of studies examining behavioral responses to
cannabinoid receptor activation used 19-Tetrahydrocannabinol
(THC), the primary phytocannabinoid in the cannabis plant.
Abbreviations: ACEA, arachidonyl-2-chloroethylamide; CNS, central nervous
system; DOP, delta opioid; KO, knockout; KOP, kappa opioid; MOP, mu opioid;
NLX, naloxone; NTI, naltrindole; THC,19-Tetrahydrocannabinol; WT, wildtype.
Because it is a partial agonist at both CB1 and CB2 receptors,
THC cannot dissociate the contribution of either cannabinoid
receptor to behavioral and affective processes related to
pain management. This is a particularly important issue in
pain studies, given recent evidence that CB2 receptors are
involved in pathological states, such as neuroinflammation and
hypersensitivity (27).
In this study, we explored possible interactions between opioid
and cannabinoid systems in themediation of antinociception and
addiction-related behaviors. To do so, we examined the effect
of the selective CB1 agonist, arachidonyl-2-chloroethylamide
(ACEA) (28), on nociception, tolerance, withdrawal, and
emotion-related behaviors in MOP or DOP receptor deficient
mice. Nociception and tolerance to this effect were assessed
in the tail immersion assay; somatic withdrawal symptoms
were measured following an injection of the opiate antagonist,
naloxone. We relied on naturalistic behaviors to assess anxiety-
like (light-dark box) and depressive-like (splash test) responses
in mice. Finally, we tested the consequences of both acute and
repeated ACEA treatments on opioid-mediated effects in order
to assess putative biphasic properties of this agonist.
MATERIALS AND METHODS
Animals
One hundred and sixty-eight male and female mice lacking
MOP or DOP receptors (MOP KO and DOP KO, respectively)
and their wildtype controls (12–24 weeks) were group housed
(2–5/cage) under standard light, temperature, and humidity
conditions (12 h light-dark cycle, 22 ± 2◦C, 55 ± 10% humidity)
with ad libitum access to food and water. Mice were generated by
homologous recombination (29, 30). The genetic background of
all mice was 50% C57/BL6J:50% 129svPas.
Research was conducted in accordance with the European
Communities Council Directive of 22 September 2010 (directive
2010/63/UE), under the guidelines of the Committee for
Research and Ethical issues of the International Association
for the Study of Pain (31). Experiments were approved by the
local ethics committee (Comité Régional d’Ethique en Matière
d’Expérimentation Animale de Strasbourg CREMEAS), and
findings are reported following the ARRIVE Guidelines for
experiments involving animals.
Drugs
ACEA (Tocris, Bio-techne, Lille, France) was dissolved in 0.9%
saline solution (supplied pre-dissolved in ethanol at 5 mg/ml)
to obtain doses of 0.15, 3, and 5 mg/kg. Naloxone (NLX) and
Naltrindole (NTI) (Sigma-Aldrich St-Quentin Fallavier, France)
were dissolved in saline solution to obtain final doses of 1 and
2.5 mg/kg, respectively. Vehicle (saline or 6% ethanol) injections
were used as controls. All drug and vehicle injections were
administered ip using 100 µl solution per 10 g bodyweight.
Behavioral Procedures
In each group, approximately equal numbers of male and female
mice were used. A total of 22 DOP KO, 49 MOP KO, and 97
WT mice were used. Mice were habituated to the facility and
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handled for one week before starting the experiments. Behavioral
tests were conducted during the light phase and performed blind
to genotype and treatment. ACEA or vehicle was administered
45min before tail immersion or light-dark tests, 35min before
the splash test, and 90min before precipitated withdrawal.
Tail Immersion
Thermal nociceptive thresholds were assessed in the tail
immersion test by gently restraining mice and immersing ∼2/3
of the tail in a water bath at 47◦C. The latency to withdraw the tail
was recorded before and after ACEA injections. Acute responses
to increasing doses of ACEA were tested in WT and MOP KO
mice. The effects of repeated ACEA injections (3 mg/kg) on
antinociception were tested in a separate group of WT and MOP
KO mice by measuring tail immersion responses on day 1 and
day 5 of treatment. Hypersensitivity to repeated treatment was
assessed 23 h after the last injection, as described previously (32).
Naloxone-Precipitated Withdrawal From ACEA
To evaluate the role of the opioid system in cannabinoid
withdrawal, WT, MOP KO, and DOP KO mice received ACEA
injections (3 mg/kg once per day for 5 days) followed by a
naloxone injection (1 mg/kg), administered 90min after the last
ACEA injection. Withdrawal behaviors were summed over a 20-
min observation period and three separate scores were computed
for each animal. First, global withdrawal scores were calculated
by summing the following values: jumping x 0.8, wet dogs shakes
x 1, paw tremors x 0.35, ptosis x 1.5, teeth chattering x 1.5,
body tremors x 1.5, and piloerection x 1.5. Second, a subcategory
of somatic signs was calculated by combining the total number
of jumps, paw tremors, and wet dog shakes. Third, signs of
discomfort reflected the sum of stretching, genital licks, and body
tremors (33).
Light-Dark Test
The light-dark test, assessing anxiety-like behavior in rodents,
employed an apparatus composed of two compartments (20 ×
20 × 25 cm), connected by a tunnel (6 × 16.5 × 20 cm) (34).
One compartment was brightly illuminated (>400 lx); the other
was dark (7 lx). Mice were placed in the dark compartment and
allowed to freely explore the apparatus for 5min while the time
spent in each compartment and the tunnel was recorded. Mice
have a natural tendency to avoid lit environments: decreased
time spent in the dark compartment is a measure of reduced
anxiety (35). WT, MOP KO, and DOP KO mice were tested
prior to drug administration (baseline; BL) and then following
ACEA injections (3 mg/kg) on days 1 and 3. The role of DOP
receptors in ACEA-induced changes in anxiety-like behavior
was assessed in WT mice by administering NTI prior to ACEA
injections; control groups received saline plus ACEA or NTI plus
vehicle.
Splash Test
The splash test (36, 37) consists of vaporizing a 20% sucrose
solution on the back fur of mice; mice initiate grooming in
response to the solution viscosity. The number of grooming
responses (head or body grooming, shakes, and scratches) and
the time spent grooming were recorded over 5min. Repeated
stress decreases grooming responses, which is reversed by
antidepressant treatment (38), providing an assay for changes
in depressive-like behavior in rodents. WT, MOP KO, and DOP
KO mice were assessed in the splash test following days 1 and 3
of ACEA treatment (3 mg/kg). As with the light-dark test, WT
mice were tested following injections NTI plus ACEA, saline plus
ACEA, or NTI plus vehicle.
Data Analyses
Statistical tests were performed using Graphpad Prism R©
statistical software (Version 6.0; La Jolla, CA, USA). Data from
the tail immersion, light-dark, and splash tests were analyzed
using a two-way analysis of variance (ANOVA) with genotype as
a within subject’s factor and dose or day of injection as repeated
factors. A 2-way ANOVA (genotype by drug) was used to assess
each category of withdrawal score. Subsequent comparisons were
conducted using Bonferroni post hoc tests. Statistical significance
was set at p< 0.05.
RESULTS
Body weight was monitored across the entire experiment with
daily weights recorded on all drug treatment days. Using body
weight prior to the first injection as a baseline, ANOVA revealed
no effect of drug (ACEA, NTI, or NTI+ ACEA) on body weights
at d5 in either WT (ACEA, 97.5% of BL; NTI, 95.1% of BL,
NTI+ACEA, 101.8% of BL), MOP KO (Vehicle, 102.7% of BL;
ACEA, 100.7% of BL), or DOP KO (Vehicle, 100.6% of BL;
ACEA, 97.9 % of BL) mice.
Thermal Nociception
As shown in Figure 1A, acute injections of ACEA had no
effect on thermal nociception in WT or MOP KO mice across
a range of doses [WT: F(3, 32) = 1.43, P = 0.24; MOP KO:
F(3, 31) = 1.86, P= 0.15]. Although MOP receptors preferentially
mediate nociceptive response in mice (30), we did not observe
any significant modification of nociceptive thresholds in this
genotype, compared toWTmice (P> 0.05). We also investigated
the effects of repeated subanalgesic doses of ACEA (Figure 1B),
revealing no drug-induced alteration in thermal nociceptive
thresholds in WT mice [F(1, 45) = 0.04, P = 0.15] and no effect
of repeated injections [F(2, 90) = 1.30, P = 0.27]. MOR KO mice
developed hypersensitivity, with decreased thermal nociceptive
thresholds after the 1st vehicle and 5th ACEA injections [Drug
X Time Interaction: F(2, 44) = 3.40, P < 0.05]. Finally, there was
no effect of chronic ACEA treatment on thermal nociceptive
thresholds in either WT or MOP KO mice, measured 23 h after
the last injection (Figure 1C) [WT: F(1, 45) = 0.40, P= 0.15; MOP
KO: F(1, 22) = 2.68, P = 0.11].
Naloxone-Precipitated Withdrawal From
ACEA
Naloxone induced increased global withdrawal scores in animals
chronically treated with ACEA [F(1, 41) = 28.85, P < 0.0001].
The effect was consistent across WT, MOP KO, and DOP KO
mice [F(2, 41) = 1.74, P = 0.16], with modest changes in all three
genotypes treated with vehicle (Figure 2A). A more detailed
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FIGURE 1 | Effects of ACEA on thermal nociceptive thresholds in wildtype (WT) (left) and MOP receptor knockout (KO) (right) mice following acute (A) or chronic (B)
injections and during a post-treatment drug-free test (C). (A) Bars represent mean (+SEM) latency (s) to withdraw the tail from a heated bath 45min after ACEA (0.15,
3, or 5 mg/kg) or vehicle injections. (B) Tail withdrawal latencies are expressed as mean (+SEM) % change from baseline (BL) following vehicle or ACEA (3 mg/kg)
administration on days 1 and 5 (d1, d5) of a 5-day dosing regime. BL was established one day prior to the first injection. (C) Tail withdrawal latencies, shown as mean
(+SEM) % change from BL, were assessed 23 h following the final ACEA or vehicle injection. ACEA = arachidonyl-2-chloroethylamide **P < 0.01; ***P < 0.001.
analysis revealed that ACEA treatment increased both somatic
symptoms [F(1, 41) = 24.45, P < 0.0001] and signs of discomfort
[F(1 41) = 3.80, P = 0.058], although the latter did not reach
statistical significance (Figures 2B,C). Differences in somatic
signs in ACEA- and vehicle-treated mice varied across genotype
[F(2, 41) = 4.50, P < 0.05], with MOP KO showing reduced signs
of withdrawal compared to WT and DOP KO mice. Signs of
discomfort were relatively low in all animals and did not differ
across the three lines [F(2, 41) = 0.97, P = 0.07].
Light-Dark Test
Figure 3A shows that there were no significant differences in
baseline levels of anxiety, measured in the light-dark test, across
WT, MOP KO, and DOP KO mice [F(2, 37) = 1.436, P =
0.25]. Repeated drug injections (ACEA with and without NTI)
decreased anxiety-like effects in WT mice (Figure 3B) [F(2, 42) =
7.93, P< 0.01], although there was no overall main effect of drug
[F(2, 21) = 0.02, P = 0.97]. Post-hoc tests revealed a significant
difference in % time spent in the dark on BL compared to d1 for
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FIGURE 2 | Effects of ACEA treatment on naloxone-precipitated withdrawal in wildtype (WT), MOP knockout (KO), and DOP KO mice. Bars represent mean (+SEM)
global withdrawal scores (A), somatic signs (B), and signs of discomfort (C) for each genotype over a 20-min observation session. Naloxone (1 mg/kg) was
administered 2 h after the last injection of vehicle or ACEA (3 mg/kg per day for 5 days). ACEA = arachidonyl-2-chloroethylamide *P < 0.05; **P < 0.01.
mice treated withNTI plus ACEA (Bonferroni post-hoc P< 0.05).
Similarly, repeated injections of ACEA increased % time in the
dark in both KO lines [F(2, 28) = 8.57, P< 0.01] (Figure 3C), due
to significant changes from BL to both d1 and d3 in MOP KO
mice (Bonferroni post-hoc P < 0.05 and P < 0.01).
Splash Test
As shown in Figure 4, grooming scores of WT controls
(Figure 4A) were higher than both MOP (Figure 4C) and DOP
(Figure 4D) KO mice following a vehicle injection, although
time spent grooming was consistent across genotypes. Statistical
analysis revealed that the effect of ACEA on grooming scores in
WT and DOP KOmice was modified with repeated testing [WT:
F(1, 23) = 7.15, P < 0.05; DOP KO: F(1, 12) = 15.50, P < 0.01].
Analysis of time spent grooming revealed a similar drug x time
interaction in these groups [WT: F(1, 23) = 15.25, P < 0.0001;
DOP KO: F(1, 12) = 16.23, P < 0.01]. These effects were due to
decreased grooming on day 1 in ACEA- vs. vehicle-treated mice
and increased drug-induced grooming on day 3 compared to day
1 (post-hoc Ps < 0.05). ACEA increased grooming score [F(1, 29)
= 17.04, P< 0.001], but not time spent grooming [F(1, 29) = 0.53,
P = 0.46], in MOP KO mice. As with WT and DOP KO mice,
both measures increased with repeated injections in this group
[grooming score: F(1, 29) = 7.30, P < 0.05; time spent grooming:
F(1, 29) = 5.38, P < 0.05]. In sum, the first ACEA injection
decreased grooming in WT and DOP KO mice, while having no
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FIGURE 3 | Effects of ACEA treatment on anxiety-like behavior in the
light-dark test for wildtype (WT), MOP knockout (KO), and DOP KO mice. (A)
Bars represent mean (+SEM) time (s) spent in the dark compartment for each
genotype over a 5-min drug-free test, which constituted baseline (BL) values.
(B) Time in the dark compartment is shown as mean (+SEM) % change from
BL, assessed on days 1 and 3 (d1, d3) in WT mice, following injections of
ACEA plus saline, ACEA combined with naltrindole (NTI), or NTI alone. (C)
Time in the dark compartment, expressed as mean (+SEM) % change from
BL, was assessed in the two KO lines on days 1 and 3 following daily
injections of vehicle or ACEA (3 mg/kg). ACEA =
arachidonyl-2-chloroethylamide. *P < 0.05; **P < 0.01.
effect in MOP KO mice. Interestingly, this prodepressive drug
effect was altered following 3 days of injections in WT mice:
grooming score returned to basal levels and time spent grooming
was increased beyond these levels. The pattern was similar in
DOP KO mice, showing increases in both measures following
the third ACEA injection. In MOP KOmice, grooming score and
time spent grooming were not significantly altered in MOP KO
mice on day 1; grooming score increased following the 3rd ACEA
injection.
We verified this biphasic effect of ACEA on depressive-like
behavior in a separate group of WTmice (Figure 4B), replicating
decreased grooming at day 1 with a return to baseline levels
by day 3 [grooming score: F(2, 42) = 4.41, P < 0.05; time spent
grooming: F(2, 42) = 9.95, P< 0.001]. Pretreatment with NTI had
no significant effect on either measure [grooming score: F(2, 21)
= 1.55, P = 0.20; time spent grooming: F(2, 21) = 1.23, P = 0.31].
DISCUSSION
The goal of this study was to clarify the role of CB1 receptors in
addiction-related behaviors and to assess potential interactions
with opioid mechanisms, specifically MOP and DOP receptors.
Extensive research over the last decades confirms an important
contribution of cannabinoid mechanisms to processes such
as antinociception, drug dependence, and emotional responses
(1, 39, 40), but many of these studies employed THC or
other nonselective compounds. Studies using receptor KO mice
confirm that both CB1 and CB2 receptors play a role in
these processes (1, 41, 42), pointing to the need to examine
behavioral effects of pharmacological tools that specifically target
each receptor. To this end, we used the selective CB1 agonist,
ACEA, as this compound has a Ki of 1.4 nM for CB1, vs. a Ki
<2000 nM for CB2, or 1,400 times greater for CB2 compared
to CB1 (43). Confirmation of compound selectivity is provided
by abolishment of neurotoxicological effects of ACEA in CB1
KO animals (44), although functional selectivity of G protein
signaling may be lost with high doses of ACEA (45).
Use of this highly specific compound revealed a distinct
pattern of behavioral effects, some of which differed from results
using other CB1 agonists. First, we show that ACEA did not
alter bodyweight, despite evidence that other CB1 agonists have
orexigenic properties in human and rodents, and that CB1
antagonists may facilitate weight loss (46, 47). We also observed
no effect of ACEA on antinociceptive thresholds across a range
of doses, contradicting previous evidence that CB agonists such
as THC, CP55,940, anandamide, or WIN are analgesic (48, 49).
We confirmed a lack of ACEA-induced antinociception in a
separate group of mice treated with a single dose and revealed
no changes in this measure with repeated injections. It is possible
that ACEA doses in our study were too low to be effective as
higher doses of THC are required to elicit analgesic responses
in the tail immersion, compared to the hot plate, test (20). It
is also possible that extending the ACEA dosing regime may
have revealed behavioral effects that were not apparent following
the protocol used in this study. At the same time, high doses
of CB agonists, such as THC, may induce hypolocomotion
and catalepsy (50), which could interfere with the behavioral
expression of pain and confound measures of antinociception. In
addition, THC produces aversive effects at higher doses, such as
anxiety and weight loss, which may explain contracictory effects
of cannabinoid agonists at high and low doses (51–53). Repeated
injections of cannabinoid agonists, such as ACEA, could lead
to poor health outcomes minimizing the ethological validity of
our findings. Importantly, doses of ACEA comparable to those
in our study reduce mechanical allodynia in mouse models of
osteoarthritic (54) and neuropathic (55) pain. A more plausible
explanation for our negative findings, therefore, is that CB1
receptors are not involved in antinociceptive responses in pain
naïve states, fitting evidence that ACEA-induced analgesia in
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FIGURE 4 | Effects of ACEA treatment on depressive-like behaviors in the splash test for wildtype (WT) (A), MOP knockout (KO) (C), and DOP KO (D) mice. Bars
represent mean (+SEM) grooming score (left) and time (s) spent grooming (right) in response to vaporization of a 20% sucrose solution on the back fur. Responses
were assessed in each genotype over a 5-min period, 45min after the first and third daily (d1, d3) injections of vehicle or ACEA (3 mg/kg). Grooming responses were
assessed in a separate group of WT mice on days 1 and 3 (d1, d3) following injections of ACEA plus saline, ACEA combined with naltrindole (NTI), or NTI alone (B).
ACEA = arachidonyl-2-chloroethylamide *P < 0.05; **P < 0.01; ***P < 0.001.
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a neuropathic model does not extend to the paw contralateral
to the injury (54). This dissociation in the effectiveness of
ACEA treatment may reflect altered endocannabinoid signaling,
including changes in CB1 receptor function, that is associated
with persistent pain states (56).
Our study also provides the first evidence of naloxone-
precipitated withdrawal following chronic ACEA treatment.
The effect was consistent across all three genotypes but was
substantially lower than symptoms observed following treatment
with a classic MOP receptor agonist, morphine (33). This general
reduction in withdrawal signs may have obscured any genotypic
differences in our study, such as decreased withdrawal in MOP
or DOP KO mice. If these do exist, they could be revealed by a
more intense treatment regime (i.e., higher dose and/or increased
number of injections). Regardless, our finding that naloxone
elicited withdrawal symptoms in ACEA-treated mice adds to
evidence of opioid-cannabinoid interactions in this behavior.
For example, cannabinoid antagonists, such as SR141716A, elicit
withdrawal symptoms following chronic morphine injections
(17, 19, 57) and opioid antagonists induce withdrawal in rodents
previously treated with cannabinoid agonists (17). Studies using
genetically modified mice confirm opioid-cannabinoid cross-
talk in drug withdrawal: naloxone-precipitated withdrawal is
decreased in CB1 receptor knockout mice following morphine
treatment (19–21) and MOP KO mice exhibit reductions
in SR141716A-induced withdrawal following chronic THC
treatment (19). The latter effect is dose dependent and
alleviated by morphine injections in wildtype mice, providing
further support for cannabinoid-opioid interactions in drug
withdrawal.
Given the reciprocal relationship between opioid and
cannabinoid systems in drug withdrawal, our observation that
ACEA treatment induced withdrawal symptoms in both MOP
and DOP KO mice seems counterintuitive. These findings
could suggest that the KOP receptor has a critical role in
cannabinoid withdrawal. This fits evidence that DOP receptors
contribute to negative affective states induced by THC (18,
20, 58), but have no role in the anxiolytic properties of the
drug (59). In addition, naloxone is a nonselective antagonist
so if a single receptor subtype is deleted (e.g., MOP or DOP),
withdrawal symptoms could be elicited through an action at the
remaining, intact receptors. This would explain why naloxone-
precipitated withdrawal following cannabinoid treatment is
not modulated in mice lacking either MOP, DOP, or KOP
receptors (18).
A novel finding in our study is that initial administration of a
CB1 agonist produces a depressive-like state, which recovers with
further drug exposure. This could explain why the rewarding
effects of cannabinoid agonists, including THC, are only revealed
in self-administration or place conditioning paradigms when
animals receive priming injections prior to training (18, 51,
53, 60, 61). Interestingly, the pro-depressive effect of acute
ACEA injections (i.e., day 1) was absent in MOP KO mice,
mimicking decreased depressive-like symptoms of this genotype
in other behavioral tests (29). Despite this initial blunting,
repeated ACEA injections reduced depressive-like symptoms in
MOP KO animals, matching behavioral effects observed in DOP
KO mice. WT mice showed a different profile: repeated ACEA
injections restored grooming scores to basal levels but increased
time spent grooming above control levels. MOP receptors,
therefore, appear to mediate the initial pro-depressive effects of
ACEA without affecting the subsequent anti-depressive effects of
repeated exposure.
In contrast to depressive-like behaviors, we observed no
effect of either acute or chronic ACEA injections on anxiety-
like responses in the light/dark box. This appears to contradict
previous findings in the elevated plus maze (54), although
decreased time spent in open arms was only observed with
higher doses of the drug. At least for another CB agonist (THC),
anxiolytic properties at low doses (59, 61) are replaced by
anxiogenic effects at higher ones (51, 61). As noted previously,
hypolocomotion and catalepsy induced by higher dose of THC
(50) could modify responses in a number of behavioral tasks
including the light-dark test, open field, and elevated plus maze.
At the very least, given that we used identical dosing procedures
in splash and light/dark tests, our findings provide evidence for
a dissociation in the effects of CB1 activation on anxiety- and
depressive-like responses in mice.
Given the key role of DOP receptors in anxiety and depression
(29), we went on to test whether pharmacological blockade of
these receptors in WT mice would alter responses in splash
or light/dark tests. The DOP receptor antagonist, NTI, was
ineffective on its own, but decreased time spent grooming in
the splash test when combined with ACEA. This reduction was
not matched by a reduction in grooming score, suggesting that
the drug combination may have disrupted a general pattern of
naturalistic behavior (i.e., grooming). Overall, our results are
consistent with previous studies: although NTI disrupts pro-
depressive or anxiogenic effects of DOP agonists (62–64), it is
ineffective when administered alone (65, 66). Our findings that
pharmacological blockade of DOP receptors has no effect on
anxiety- or depressive-like behaviors conflicts with studies using
genetically modified mice (67), suggesting that developmental
adaptations impact the function of these receptors in emotional
expression.
In sum, our results help to clarify how opioid and
cannabinoid systems interact in behavioral processes associated
with addiction. The use of a selective CB1 agonist revealed no
involvement of this receptor in either antinociception or anxiety-
like behaviors in mice. In contrast, repeated activation of CB1
receptors induced opioid-dependent withdrawal symptoms and
produced a biphasic effect on depressive-like symptoms. In the
long-term, this information could facilitate the development of
new pain medications that reduce the incidence of affective and
substance use disorders that currently characterize long-term
opioid use.
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